- Home
- AGMH vs HSCS Comparison
AGMH vs HSCS Comparison
Compare AGMH & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- HSCS
- Stock Information
- Founded
- AGMH 2015
- HSCS 2007
- Country
- AGMH Hong Kong
- HSCS United States
- Employees
- AGMH N/A
- HSCS N/A
- Industry
- AGMH EDP Services
- HSCS Medical Specialities
- Sector
- AGMH Technology
- HSCS Health Care
- Exchange
- AGMH Nasdaq
- HSCS Nasdaq
- Market Cap
- AGMH 3.5M
- HSCS 3.7M
- IPO Year
- AGMH 2018
- HSCS 2022
- Fundamental
- Price
- AGMH $1.97
- HSCS $3.65
- Analyst Decision
- AGMH
- HSCS Strong Buy
- Analyst Count
- AGMH 0
- HSCS 2
- Target Price
- AGMH N/A
- HSCS $13.00
- AVG Volume (30 Days)
- AGMH 67.6K
- HSCS 119.8K
- Earning Date
- AGMH 05-13-2025
- HSCS 09-11-2025
- Dividend Yield
- AGMH N/A
- HSCS N/A
- EPS Growth
- AGMH N/A
- HSCS N/A
- EPS
- AGMH 6.43
- HSCS N/A
- Revenue
- AGMH $32,044,575.00
- HSCS $4,350.00
- Revenue This Year
- AGMH N/A
- HSCS $21,003.45
- Revenue Next Year
- AGMH N/A
- HSCS $533.33
- P/E Ratio
- AGMH $0.29
- HSCS N/A
- Revenue Growth
- AGMH N/A
- HSCS N/A
- 52 Week Low
- AGMH $1.09
- HSCS $2.36
- 52 Week High
- AGMH $109.50
- HSCS $6.47
- Technical
- Relative Strength Index (RSI)
- AGMH 35.63
- HSCS 50.13
- Support Level
- AGMH $1.94
- HSCS $3.25
- Resistance Level
- AGMH $2.43
- HSCS $3.93
- Average True Range (ATR)
- AGMH 0.17
- HSCS 0.32
- MACD
- AGMH -0.00
- HSCS 0.04
- Stochastic Oscillator
- AGMH 13.21
- HSCS 65.85
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.